Recent Finacing
Recent Raise
Belgian biopharmaceutical company developing a monoclonal antibody targeting CD45RC to restore immune tolerance for autoimmune and inflammatory diseases, aiming for durable remissions with fewer side effects than standard immunosuppressants.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
